Context Therapeutics
CNTX
42 hedge funds and large institutions have $111M invested in Context Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
24% more funds holding
Funds holding: 34 → 42 (+8)
0.47% less ownership
Funds ownership: 76.05% → 75.58% (-0.47%)
3% less capital invested
Capital invested by funds: $114M → $111M (-$3.17M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$4.11M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.02M |
| 3 |
Blackstone Inc
New York
|
+$1.33M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$555K |
| 5 |
Millennium Management
New York
|
+$319K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.53M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.68M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.07M |
| 4 |
ACM
Altium Capital Management
New York
|
-$722K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$661K |
CNTX Hedge Fund Activity: Q3 2024 in Review
42 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q3 2024, worth a combined $111M — down 2.8% from $114M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CNTX positions and 6 closed out — a net gain of 8 holders — while 6 added to existing stakes and 11 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $4.11M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $4.53M sold.
- 42 institutional investors held Context Therapeutics (CNTX) as of Q3 2024, up from 34 in Q2 2024.
- Funds reported $111M of Context Therapeutics stock for Q3 2024, down 2.8% quarter-over-quarter.
- 14 funds opened new Context Therapeutics positions in Q3 2024 and 6 closed out, a net change of +8 holders.
- The largest Context Therapeutics buyer in Q3 2024 was Franklin Resources, an estimated $4.11M added.
- The largest Context Therapeutics seller in Q3 2024 was Driehaus Capital Management, an estimated $4.53M sold.
Based on aggregated 13F filings for Q3 2024.